News

The Food and Drug Administration (FDA) has cleared Lumipulse G for U.S. commercialization as the first blood-based test that ...
The FDA has cleared the first-ever blood test for early Alzheimer's detection, which the agency says reduces the need for ...
The Food and Drug Administration cleared a new kind of test for Alzheimer’s disease designed to be more accessible and less ...
The FDA has approved the Lumipulse Plasma Ratio test, a groundbreaking blood test for early dementia detection. This less ...
The Food and Drug Administration (FDA) announced Friday it had cleared a new test to help diagnose adults with Alzheimer’s ...
Japan-based Fujirebio's test, which helps doctors diagnose Alzheimer's disease, is intended for patients with signs of ...
The FDA said it has issued its first official green light for a blood test to help diagnose Alzheimer’s disease, adding that ...
The first in vitro diagnostic device that uses blood samples to detect Alzheimer disease has been granted marketing clearance ...
Today, the FDA's approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, marking a pivotal moment in the fight against ...
The blood test, known as the Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio, can be used to detect amyloid plaques ...
(Reuters) -The U.S. Food and Drug Administration said on Friday it has cleared Fujirebio Diagnostics' blood test to diagnose ...
The Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma Ratio is for the early detection of amyloid plaques associated with Alzheimer’s disease in symptomatic adults 55 years and older.